Can a simple inhaled antibiotic stop ventilator pneumonia?
NCT ID NCT06834971
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether inhaling an antibiotic called colistin can prevent ventilator-associated pneumonia (VAP) in ICU patients at high risk for drug-resistant infections. About 508 adults on breathing machines for at least two days will receive either colistin or a placebo via nebulizer for three days. The goal is to see if this short treatment lowers the number of patients who develop VAP within 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
colistin (an antibiotic)
What this could lead to
If it works, this could offer a simple way to prevent a serious lung infection in ICU patients on breathing machines.
What could go wrong
This is an early-stage trial with 508 participants, so results may not apply to all patients. Colistin can cause kidney or nerve problems, and the infection may still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENTILATOR-ASSOCIATED PNEUMONIA (VAP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qilu Hospital of Shandong university
RECRUITINGJinan, Shandong, 250000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact